Emerging therapeutic targets in esophageal adenocarcinoma

Oncotarget

Volumn 7, Issue 30, 2016, Pages 48644-48655

  Gaur, Puja ^a   Hunt, Clayton R ^a   Pandita, Tej K ^a  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

Cancer stem cells; Chemoradioresistance; Esophageal adenocarcinoma; Genetic and epigenetic targets; Immunotherapy

Indexed keywords

FLUOROURACIL; GENOMIC DNA; IPILIMUMAB; IRINOTECAN; METFORMIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIVOLUMAB; PEMBROLIZUMAB; PLATINUM DERIVATIVE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; RAMUCIRUMAB; TAXANE DERIVATIVE; TRASTUZUMAB; TUMOR MARKER; TELOMERASE;

ADJUVANT CHEMORADIOTHERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER GENETICS; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RESEARCH; CANCER STEM CELL; CHEMORADIOTHERAPY; DNA METHYLATION; DRUG BINDING SITE; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG TARGETING; EPIGENETICS; ESOPHAGEAL ADENOCARCINOMA; HUMAN; IMMUNOTHERAPY; INTERMETHOD COMPARISON; MULTICENTER STUDY (TOPIC); NONHUMAN; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE; TUMOR IMMUNITY; ADENOCARCINOMA; BIOLOGICAL THERAPY; DRUG RESISTANCE; ESOPHAGUS RESECTION; ESOPHAGUS TUMOR; GENETIC EPIGENESIS; GENETICS; INCIDENCE; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOADJUVANT THERAPY; PROCEDURES; QUALITY OF LIFE; SIGNAL TRANSDUCTION; TRANSPLANTATION; TREATMENT OUTCOME; TRENDS; UNITED STATES;

ADENOCARCINOMA; BIOLOGICAL THERAPY; BIOMARKERS, TUMOR; CHEMORADIOTHERAPY; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; HUMANS; IMMUNOTHERAPY; INCIDENCE; MOLECULAR TARGETED THERAPY; NEOADJUVANT THERAPY; NEOPLASTIC STEM CELLS; QUALITY OF LIFE; SIGNAL TRANSDUCTION; TELOMERASE; TREATMENT OUTCOME; UNITED STATES;

EID: 84982803883     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8777     Document Type: Review

References (108)

1. Prithviraj GK, Baksh K, Fulp W, Meredith K, Hoffe S, Shridhar R and Almhanna K. Carboplatin and paclitaxel as first-line treatment of unresectable or metastatic esophageal or gastric cancer. Dis Esophagus. 2014.
2. National Cancer Institute: Surveillance, Epidemiology, and End Results Program. Website: http://seer.cancer.gov/statfacts/html/esoph.html. (Accessed Dec 20, 2015).
3. Gaur P, Kim MP and Dunkin BJ. Esophageal cancer: Recent advances in screening, targeted therapy, and management. J Carcinog. 2014; 13:11.
4. Shapiro J, van Lanschot JJ, Hulshof MC, van Hagen P, van Berge Henegouwen MI, Wijnhoven BP, van Laarhoven HW, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015; 16(9):1090-1098.
5. Courrech Staal EF, Aleman BM, Boot H, van Velthuysen ML, van Tinteren H and van Sandick JW. Systematic review of the benefits and risks of neoadjuvant chemoradiation for oesophageal cancer. Br J Surg. 2010; 97(10):1482-1496.
6. Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D and Mayer R. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008; 26(7):1086-1092.
7. Meredith KL, Weber JM, Turaga KK, Siegel EM, McLoughlin J, Hoffe S, Marcovalerio M, Shah N, Kelley S and Karl R. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer. Ann Surg Oncol. 2010; 17(4):1159-1167.
8. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012; 366(22):2074-2084.
9. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N and Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996; 335(7):462-467.
10. IBurmeister BH, Thomas JM, Burmeister EA, Walpole ET, Harvey JA, Thomson DB, Barbour AP, Gotley DC and Smithers BM. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. Eur J Cancer. 2011; 47(3):354-360.
11. Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, Gebski V and Australasian Gastro-Intestinal Trials G. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011; 12(7):681-692.
12. Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, Langer P, Engenhart-Cabillic R, Bitzer M, Konigsrainer A, Budach W and Wilke H. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009; 27(6):851-856.
13. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J and Australasian Gastro-Intestinal Trials G. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007; 8(3):226-234.
14. Denham JW, Burmeister BH, Lamb DS, Spry NA, Joseph DJ, Hamilton CS, Yeoh E, O'Brien P and Walker QJ. Factors influencing outcome following radio-chemotherapy for oesophageal cancer. The Trans Tasman Radiation Oncology Group (TROG). Radiother Oncol. 1996; 40(1):31-43.
15. Urschel JD and Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg. 2003; 185(6):538-543.
16. Chirieac LR, Swisher SG, Ajani JA, Komaki RR, Correa AM, Morris JS, Roth JA, Rashid A, Hamilton SR and Wu TT. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005; 103(7):1347-1355.
17. Hennequin C and Favaudon V. Biological basis for chemoradiotherapy interactions. Eur J Cancer. 2002; 38(2):223-230.
18. Kleinberg L, Gibson MK and Forastiere AA. Chemoradiotherapy for localized esophageal cancer: regimen selection and molecular mechanisms of radiosensitization. Nat Clin Pract Oncol. 2007; 4(5):282-294.
19. Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA and Kelsen DP. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002; 20(5):1167-1174.
20. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-697.
21. Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebocontrolled, phase 3 trial. Lancet. 2014; 383(9911):31-39.
22. Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastrooesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014; 15(11):1224-1235.
23. Kothari N and Almhanna K. Current status of novel agents in advanced gastroesophageal adenocarcinoma. J Gastrointest Oncol. 2015; 6(1):60-74.
24. Crosby T, Hurt CN, Falk S, Gollins S, Mukherjee S, Staffurth J, Ray R, Bashir N, Bridgewater JA, Geh JI, Cunningham D, Blazeby J, Roy R, et al. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol. 2013; 14(7):627-637.
25. Jordan CT, Guzman ML and Noble M. Cancer stem cells. N Engl J Med. 2006; 355(12):1253-1261.
26. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C and De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007; 445(7123):111-115.
27. Gaur P, Sceusi EL, Samuel S, Xia L, Fan F, Zhou Y, Lu J, Tozzi F, Lopez-Berestein G, Vivas-Mejia P, Rashid A, Fleming JB, Abdalla EK, et al. Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology. 2011; 141(5):1728-1737.
28. Nguyen GH, Murph MM and Chang JY. Cancer stem cell radioresistance and enrichment: where frontline radiation therapy may fail in lung and esophageal cancers. Cancers (Basel). 2011; 3(1):1232-1252.
29. Huang D, Gao Q, Guo L, Zhang C, Jiang W, Li H, Wang J, Han X, Shi Y and Lu SH. Isolation and identification of cancer stem-like cells in esophageal carcinoma cell lines. Stem Cells Dev. 2009; 18(3):465-473.
30. Ajani JA, Wang X, Song S, Suzuki A, Taketa T, Sudo K, Wadhwa R, Hofstetter WL, Komaki R, Maru DM, Lee JH, Bhutani MS, Weston B, et al. ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients. Mol Oncol. 2014; 8(1):142-149.
31. Honjo S, Ajani JA, Scott AW, Chen Q, Skinner HD, Stroehlein J, Johnson RL and Song S. Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer. Int J Oncol. 2014; 45(2):567-574.
32. Zhang Y, Zhang X, Wang J, Shen Y, Tang X, Yu F and Wang R. Expression and Function of PPARs in Cancer Stem Cells. Curr Stem Cell Res Ther. 2015.
33. Zhang X, Komaki R, Wang L, Fang B and Chang JY. Treatment of radioresistant stem-like esophageal cancer cells by an apoptotic gene-armed, telomerase-specific oncolytic adenovirus. Clin Cancer Res. 2008; 14(9):2813-2823.
34. Sawant SG, Gregoire V, Dhar S, Umbricht CB, Cvilic S, Sukumar S and Pandita TK. Telomerase activity as a measure for monitoring radiocurability of tumor cells. FASEB J. 1999; 13(9):1047-1054.
35. Blackburn EH, Greider CW, Henderson E, Lee MS, Shampay J and Shippen-Lentz D. Recognition and elongation of telomeres by telomerase. Genome. 1989; 31(2):553-560.
36. Pandita RK, Chow TT, Udayakumar D, Bain AL, Cubeddu L, Hunt CR, Shi W, Horikoshi N, Zhao Y, Wright WE, Khanna KK, Shay JW and Pandita TK. Single-strand DNA-binding protein SSB1 facilitates TERT recruitment to telomeres and maintains telomere G-overhangs. Cancer Res. 2015; 75(5):858-869.
37. Che SM, Zhang XZ, Liu XL, Chen X and Hou L. The radiosensitization effect of NS398 on esophageal cancer stem cell-like radioresistant cells. Dis Esophagus. 2011; 24(4):265-273.
38. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-760.
39. Almanaa TN, Geusz ME and Jamasbi RJ. A new method for identifying stem-like cells in esophageal cancer cell lines. J Cancer. 2013; 4(7):536-548.
40. Taylor C, Loomans HA, Le Bras GF, Koumangoye RB, Romero-Morales AI, Quast LL, Zaika AI, El-Rifai W, Andl T and Andl CD. Activin a signaling regulates cell invasion and proliferation in esophageal adenocarcinoma. Oncotarget. 2015; 6(33):34228-34244.
41. Wang Z, Da Silva TG, Jin K, Han X, Ranganathan P, Zhu X, Sanchez-Mejias A, Bai F, Li B, Fei DL, Weaver K, Carpio RV, Moscowitz AE, et al. Notch signaling drives stemness and tumorigenicity of esophageal adenocarcinoma. Cancer Res. 2014; 74(21):6364-6374.
42. Ross-Innes CS, Becq J, Warren A, Cheetham RK, Northen H, O'Donovan M, Malhotra S, di Pietro M, Ivakhno S, He M, Weaver JM, Lynch AG, Kingsbury Z, et al. Whole-genome sequencing provides new insights into the clonal architecture of Barrett's esophagus and esophageal adenocarcinoma. Nat Genet. 2015; 47(9):1038-1046.
43. Dulak AM, Stojanov P, Peng S, Lawrence MS, Fox C, Stewart C, Bandla S, Imamura Y, Schumacher SE, Shefler E, McKenna A, Carter SL, Cibulskis K, et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet. 2013; 45(5):478-486.
44. Weaver JM, Ross-Innes CS, Shannon N, Lynch AG, Forshew T, Barbera M, Murtaza M, Ong CA, Lao-Sirieix P, Dunning MJ, Smith L, Smith ML, Anderson CL, et al. Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nat Genet. 2014; 46(8):837-843.
45. Kastelein F, Biermann K, Steyerberg EW, Verheij J, Kalisvaart M, Looijenga LH, Stoop HA, Walter L, Kuipers EJ, Spaander MC, Bruno MJ and ProBar-Study G. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus. Gut. 2013; 62(12):1676-1683.
46. Singh SP, Lipman J, Goldman H, Ellis FH, Jr., Aizenman L, Cangi MG, Signoretti S, Chiaur DS, Pagano M and Loda M. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res. 1998; 58(8):1730-1735.
47. Sikkema M, Kerkhof M, Steyerberg EW, Kusters JG, van Strien PM, Looman CW, van Dekken H, Siersema PD and Kuipers EJ. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study. Am J Gastroenterol. 2009; 104(11):2673-2680.
48. Weston AP, Banerjee SK, Sharma P, Tran TM, Richards R and Cherian R. p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression. Am J Gastroenterol. 2001; 96(5):1355-1362.
49. Song Y, Li L, Ou Y, Gao Z, Li E, Li X, Zhang W, Wang J, Xu L, Zhou Y, Ma X, Liu L, Zhao Z, et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature. 2014; 509(7498):91-95.
50. Dulak AM, Schumacher SE, van Lieshout J, Imamura Y, Fox C, Shim B, Ramos AH, Saksena G, Baca SC, Baselga J, Tabernero J, Barretina J, Enzinger PC, et al. Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res. 2012; 72(17):4383-4393.
51. Goh XY, Rees JR, Paterson AL, Chin SF, Marioni JC, Save V, O'Donovan M, Eijk PP, Alderson D, Ylstra B, Caldas C and Fitzgerald RC. Integrative analysis of array-comparative genomic hybridisation and matched gene expression profiling data reveals novel genes with prognostic significance in oesophageal adenocarcinoma. Gut. 2011; 60(10):1317-1326.
52. Frankel A, Armour N, Nancarrow D, Krause L, Hayward N, Lampe G, Smithers BM and Barbour A. Genome-wide analysis of esophageal adenocarcinoma yields specific copy number aberrations that correlate with prognosis. Genes Chromosomes Cancer. 2014; 53(4):324-338.
53. Shiraishi H, Mikami T, Aida J, Nakamura K, Izumiyama-Shimomura N, Arai T, Watanabe M, Okayasu I and Takubo K. Telomere shortening in Barrett's mucosa and esophageal adenocarcinoma and its association with loss of heterozygosity. Scand J Gastroenterol. 2009; 44(5):538-544.
54. Nones K, Waddell N, Wayte N, Patch AM, Bailey P, Newell F, Holmes O, Fink JL, Quinn MC, Tang YH, Lampe G, Quek K, Loffler KA, et al. Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis. Nat Commun. 2014; 5:5224.
55. Meena J, Rudolph KL and Gunes C. Telomere Dysfunction, Chromosomal Instability and Cancer. Recent Results Cancer Res. 2015; 200:61-79.
56. Qi Z and Mi R. Inhibition of human telomerase reverse transcriptase in vivo and in vitro for retroviral vector-based antisense oligonucleotide therapy in ovarian cancer. Cancer Gene Ther. 2016; 23(1):36-42.
57. Agarwal M, Pandita S, Hunt CR, Gupta A, Yue X, Khan S, Pandita RK, Pratt D, Shay JW, Taylor JS and Pandita TK. Inhibition of telomerase activity enhances hyperthermiamediated radiosensitization. Cancer Res. 2008; 68(9):3370-3378.
58. Mancini J, Rousseau P, Castor KJ, Sleiman HF and Autexier C. Platinum(II) phenanthroimidazole G-quadruplex ligand induces selective telomere shortening in A549 cancer cells. Biochimie. 2016; 121:287-297.
59. Crees Z, Girard J, Rios Z, Botting GM, Harrington K, Shearrow C, Wojdyla L, Stone AL, Uppada SB, Devito JT and Puri N. Oligonucleotides and G-quadruplex stabilizers: targeting telomeres and telomerase in cancer therapy. Curr Pharm Des. 2014; 20(41):6422-6437.
60. Ruden M and Puri N. Novel anticancer therapeutics targeting telomerase. Cancer Treat Rev. 2013; 39(5):444-456.
61. Mengual Gomez DL, Armando RG, Cerrudo CS, Ghiringhelli PD and Gomez DE. Telomerase as a cancer target. Development of new molecules. Curr Top Med Chem. 2016.
62. Shammas MA, Qazi A, Batchu RB, Bertheau RC, Wong JY, Rao MY, Prasad M, Chanda D, Ponnazhagan S, Anderson KC, Steffes CP, Munshi NC, De Vivo I, et al. Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo. Clin Cancer Res. 2008; 14(15):4971-4980.
63. Lu R, Pal J, Buon L, Nanjappa P, Shi J, Fulciniti M, Tai YT, Guo L, Yu M, Gryaznov S, Munshi NC and Shammas MA. Targeting homologous recombination and telomerase in Barrett's adenocarcinoma: impact on telomere maintenance, genomic instability and tumor growth. Oncogene. 2014; 33(12):1495-1505.
64. Ahrens TD, Werner M and Lassmann S. Epigenetics in esophageal cancers. Cell Tissue Res. 2014; 356(3):643-655.
65. Jones PA and Baylin SB. The epigenomics of cancer. Cell. 2007; 128(4):683-692.
66. Kailasam A, Mittal SK and Agrawal DK. Epigenetics in the Pathogenesis of Esophageal Adenocarcinoma. Clin Transl Sci. 2015; 8(4):394-402.
67. Ramzan Z, Nassri AB and Huerta S. The use of imaging and biomarkers in diagnosing Barrett's esophagus and predicting the risk of neoplastic progression. Expert Rev Mol Diagn. 2014; 14(5):575-591.
68. Herman JG and Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003; 349(21):2042-2054.
69. Karsli-Ceppioglu S, Dagdemir A, Judes G, Ngollo M, Penault-Llorca F, Pajon A, Bignon YJ and Bernard-Gallon D. Epigenetic mechanisms of breast cancer: an update of the current knowledge. Epigenomics. 2014; 6(6):651-664.
70. Okugawa Y, Grady WM and Goel A. Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers. Gastroenterology. 2015; 149(5):1204-1225 e1212.
71. Clement G, Braunschweig R, Pasquier N, Bosman FT and Benhattar J. Methylation of APC, TIMP3, and TERT: a new predictive marker to distinguish Barrett's oesophagus patients at risk for malignant transformation. J Pathol. 2006; 208(1):100-107.
72. Tischoff I, Hengge UR, Vieth M, Ell C, Stolte M, Weber A, Schmidt WE and Tannapfel A. Methylation of SOCS-3 and SOCS-1 in the carcinogenesis of Barrett's adenocarcinoma. Gut. 2007; 56(8):1047-1053.
73. Bian YS, Osterheld MC, Fontolliet C, Bosman FT and Benhattar J. p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus. Gastroenterology. 2002; 122(4):1113-1121.
74. Chen J, O'Shea C, Fitzpatrick JE, Koster MI and Koch PJ. Loss of Desmocollin 3 in skin tumor development and progression. Mol Carcinog. 2012; 51(7):535-545.
75. Knosel T, Chen Y, Hotovy S, Settmacher U, Altendorf-Hofmann A and Petersen I. Loss of desmocollin 1-3 and homeobox genes PITX1 and CDX2 are associated with tumor progression and survival in colorectal carcinoma. Int J Colorectal Dis. 2012; 27(11):1391-1399.
76. Wang Q, Peng D, Zhu S, Chen Z, Hu T, Soutto M, Saad R, Zhang S and Ei-Rifai W. Regulation of Desmocollin3 Expression by Promoter Hypermethylation is Associated with Advanced Esophageal Adenocarcinomas. J Cancer. 2014; 5(6):457-464.
77. Xu E, Gu J, Hawk ET, Wang KK, Lai M, Huang M, Ajani J and Wu X. Genome-wide methylation analysis shows similar patterns in Barrett's esophagus and esophageal adenocarcinoma. Carcinogenesis. 2013; 34(12):2750-2756.
78. Hamilton JP, Sato F, Greenwald BD, Suntharalingam M, Krasna MJ, Edelman MJ, Doyle A, Berki AT, Abraham JM, Mori Y, Kan T, Mantzur C, Paun B, et al. Promoter methylation and response to chemotherapy and radiation in esophageal cancer. Clin Gastroenterol Hepatol. 2006; 4(6):701-708.
79. Kaz AM, Wong CJ, Luo Y, Virgin JB, Washington MK, Willis JE, Leidner RS, Chak A and Grady WM. DNA methylation profiling in Barrett's esophagus and esophageal adenocarcinoma reveals unique methylation signatures and molecular subclasses. Epigenetics. 2011; 6(12):1403-1412.
80. Langer R, Mutze K, Becker K, Feith M, Ott K, Hofler H and Keller G. Expression of class I histone deacetylases (HDAC1 and HDAC2) in oesophageal adenocarcinomas: an immunohistochemical study. J Clin Pathol. 2010; 63(11):994-998.
81. Ahrens TD, Timme S, Hoeppner J, Ostendorp J, Hembach S, Follo M, Hopt UT, Werner M, Busch H, Boerries M and Lassmann S. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine. Epigenetics. 2015; 10(5):431-445.
82. Miyashita T, Tajima H, Munemoto M, Shah FA, Harmon JW, Watanabe T, Shoji M, Okamoto K, Nakanuma S, Sakai S, Kinoshita J, Makino I, Nakamura K, et al. Impact of histone deacetylase 1 and metastasis-associated gene 1 expression in esophageal carcinogenesis. Oncol Lett. 2014; 8(2):758-764.
83. Nguyen GH, Schetter AJ, Chou DB, Bowman ED, Zhao R, Hawkes JE, Mathe EA, Kumamoto K, Zhao Y, Budhu A, Hagiwara N, Wang XW, Miyashita M, et al. Inflammatory and microRNA gene expression as prognostic classifier of Barrett's-associated esophageal adenocarcinoma. Clin Cancer Res. 2010; 16(23):5824-5834.
84. Wijnhoven BP, Hussey DJ, Watson DI, Tsykin A, Smith CM, Michael MZ and South Australian Oesophageal Research G. MicroRNA profiling of Barrett's oesophagus and oesophageal adenocarcinoma. Br J Surg. 2010; 97(6):853-861.
85. Huan L, Bao C, Chen D, Li Y, Lian J, Ding J, Huang S, Liang L and He X. MiR-127-5p targets the biliverdin reductase B/NF-kappaB pathway to suppress cell growth in hepatocellular carcinoma cells. Cancer Sci. 2015.
86. ILi D, Li Z, Xiong J, Gong B, Zhang G, Cao C, Jie Z, Liu Y, Cao Y, Yan Y, Xiong H, Qiu L, Yang M, et al. MicroRNA-212 functions as an epigenetic-silenced tumor suppressor involving in tumor metastasis and invasion of gastric cancer through down-regulating PXN expression. Am J Cancer Res. 2015; 5(10):2980-2997.
87. Zheng M, Sun X, Li Y and Zuo W. MicroRNA-145 inhibits growth and migration of breast cancer cells through targeting oncoprotein ROCK1. Tumour Biol. 2015.
88. Smith CM, Watson DI, Michael MZ and Hussey DJ. MicroRNAs, development of Barrett's esophagus, and progression to esophageal adenocarcinoma. World J Gastroenterol. 2010; 16(5):531-537.
89. Huang J, Zhang SY, Gao YM, Liu YF, Liu YB, Zhao ZG and Yang K. MicroRNAs as oncogenes or tumour suppressors in oesophageal cancer: potential biomarkers and therapeutic targets. Cell Prolif. 2014; 47(4):277-286.
90. Bansal A, Lee IH, Hong X, Anand V, Mathur SC, Gaddam S, Rastogi A, Wani SB, Gupta N, Visvanathan M, Sharma P and Christenson LK. Feasibility of mcroRNAs as biomarkers for Barrett's Esophagus progression: a pilot cross-sectional, phase 2 biomarker study. Am J Gastroenterol. 2011; 106(6):1055-1063.
91. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-723.
92. Linsley PS, Bradshaw J, Greene J, Peach R, Bennett KL and Mittler RS. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity. 1996; 4(6):535-543.
93. Peggs KS, Quezada SA, Chambers CA, Korman AJ and Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med. 2009; 206(8):1717-1725.
94. Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, Linsley PS, Thompson CB and Riley JL. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol. 2005; 25(21):9543-9553.
95. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000; 192(7):1027-1034.
96. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-2454.
97. Raufi AG and Klempner SJ. Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations. J Gastrointest Oncol. 2015; 6(5):561-569.
98. Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR and Fu YX. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014; 124(2):687-695.
99. Zhang B, Bowerman NA, Salama JK, Schmidt H, Spiotto MT, Schietinger A, Yu P, Fu YX, Weichselbaum RR, Rowley DA, Kranz DM and Schreiber H. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med. 2007; 204(1):49-55.
100. Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS and Workman P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol. 2008; 8(4):393-412.
101. Zhan M and Han ZC. Phosphatidylinositide 3-kinase/AKT in radiation responses. Histol Histopathol. 2004; 19(3):915-923.
102. Phillips WA, Russell SE, Ciavarella ML, Choong DY, Montgomery KG, Smith K, Pearson RB, Thomas RJ and Campbell IG. Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett's esophagus. Int J Cancer. 2006; 118(10):2644-2646.
103. Beales IL, Ogunwobi O, Cameron E, El-Amin K, Mutungi G and Wilkinson M. Activation of Akt is increased in the dysplasia-carcinoma sequence in Barrett's oesophagus and contributes to increased proliferation and inhibition of apoptosis: a histopathological and functional study. BMC Cancer. 2007; 7:97.
104. Pal J, Fulciniti M, Nanjappa P, Buon L, Tai YT, Tassone P, Munshi NC and Shammas MA. Targeting PI3K and RAD51 in Barrett's adenocarcinoma: impact on DNA damage checkpoints, expression profile and tumor growth. Cancer Genomics Proteomics. 2012; 9(2):55-66.
105. Schuurbiers OC, Kaanders JH, van der Heijden HF, Dekhuijzen RP, Oyen WJ and Bussink J. The PI3-K/AKTpathway and radiation resistance mechanisms in non-small cell lung cancer. J Thorac Oncol. 2009; 4(6):761-767.
106. Zhang T, Cui GB, Zhang J, Zhang F, Zhou YA, Jiang T and Li XF. Inhibition of PI3 kinases enhances the sensitivity of non-small cell lung cancer cells to ionizing radiation. Oncol Rep. 2010; 24(6):1683-1689.
107. Ceccaldi R, Rondinelli B and D'Andrea AD. Repair Pathway Choices and Consequences at the Double-Strand Break. Trends Cell Biol. 2015.
108. Taki T, Ohnishi T, Yamamoto A, Hiraga S, Arita N, Izumoto S, Hayakawa T and Morita T. Antisense inhibition of the RAD51 enhances radiosensitivity. Biochem Biophys Res Commun. 1996; 223(2):434-438.